{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:28:34Z","timestamp":1793953714562,"version":"4.8.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["akdh.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.akdh.2025.12.001","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:18:52Z","timestamp":1770844732000},"page":"78-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era"],"prefix":"10.1053","volume":"33","author":[{"given":"Federico","family":"Yandian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.akdh.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Nephron"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/j.ackd.2019.12.003","article-title":"C3 glomerulopathy: pathogenesis and treatment","volume":"27","author":"Ahmad","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1053\/j.akdh.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","article-title":"Validation of a histologic scoring index for C3 Glomerulopathy","volume":"77","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.akdh.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257397","article-title":"Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: a retrospective analysis of data from the Japan Renal Biopsy Registry","volume":"16","author":"Nakagawa","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfac148","article-title":"Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation","volume":"38","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ekir.2024.10.008","article-title":"Outcome of patients transplanted for C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis","volume":"10","author":"Halfon","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ndt\/gfw290","article-title":"Characterization of C3 in C3 glomerulopathy","volume":"32","author":"Sethi","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.001_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years\u2019 experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis \u2014 A new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ki.2013.340","article-title":"Toward a working definition of C3 glomerulopathy by immunofluorescence","volume":"85","author":"Hou","year":"2014","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2014.217","article-title":"Histopathology of MPGN and C3 glomerulopathies","volume":"11","author":"Cook","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.kint.2024.02.013","article-title":"Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy","volume":"105","author":"Madden","year":"2024","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.001_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae161","article-title":"Apolipoprotein E in dense deposits: a parting of the ways in C3 glomerulopathy","volume":"17","author":"Tavares","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MNH.0000000000000412","article-title":"Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome","volume":"27","author":"Cook","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex\u2013mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/ndt\/gfs288","article-title":"Idiopathic membranoproliferative glomerulonephritis: does it exist?","volume":"27","author":"Fervenza","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2020.05.053","article-title":"Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties","volume":"98","author":"Fakhouri","year":"2020","journal-title":"Kidney Int"},{"key":"10.1053\/j.akdh.2025.12.001_bib29","first-page":"3399","article-title":"Phase 3, randomized, multicenter study to evaluate the efficacy and safety of pegcetcaoplan in treatment of C3G or IC-MPGN","volume":"36","author":"Dixon","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ekir.2023.12.007","article-title":"C3 glomerulopathy: novel treatment paradigms","volume":"9","author":"Estebanez","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ekir.2023.10.022","article-title":"Iptacopan in idiopathic immune complex\u2013mediated membranoproliferative glomerulonephritis: protocol of the APPARENT multicenter, randomized phase 3 study","volume":"9","author":"Vivarelli","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfab281","article-title":"Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment","volume":"38","author":"Noris","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/ndt\/gfae243","article-title":"Acquired and genetic drivers of C3 and C5 convertase dysregulation in C3 glomerulopathy and immunoglobulin-associated MPGN","volume":"40","author":"Roquigny","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.akdh.2024.05.002","article-title":"Update on C3 Glomerulopathy","volume":"31","author":"Wooden","year":"2024","journal-title":"Adv Kidney Dis Heal"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/imr.13168","article-title":"The susceptibility of the kidney to alternative pathway activation\u2014A hypothesis","volume":"313","author":"Thurman","year":"2023","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfae245","article-title":"Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGN","volume":"40","author":"Meuleman","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","article-title":"C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase","volume":"116","author":"Daha","year":"1976","journal-title":"J Immunol"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1073\/pnas.74.9.3980","article-title":"Heterogeneity of nephritic factor and its identification as an immunoglobulin","volume":"74","author":"Davis","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.001_bib40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00467-018-3989-0","article-title":"Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"34","author":"Noris","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.akdh.2025.12.001_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1036136","article-title":"Challenges in diagnostic testing of nephritic factors","volume":"13","author":"Michels","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ekir.2023.11.025","article-title":"Defining nephritic factors as diverse drivers of systemic complement dysregulation in C3 Glomerulopathy","volume":"9","author":"Hauer","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib44","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.001_bib45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","article-title":"C4 nephritic factors in C3 glomerulopathy: a case series","volume":"70","author":"Zhang","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.001_bib46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ckj\/sfw090","article-title":"C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome","volume":"9","author":"Lloyd","year":"2016","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib47","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.nefro.2017.03.012","article-title":"Gammapat\u00edas monoclonales de significado renal","volume":"37","author":"Caravaca-Font\u00e1n","year":"2017","journal-title":"Nefrolog\u00eda"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.001_bib51","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.001_bib52","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","article-title":"Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H","volume":"163","author":"Jokiranta","year":"1999","journal-title":"J Immunol"},{"key":"10.1053\/j.akdh.2025.12.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.001_bib54","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2215\/CJN.00320121","article-title":"C3 glomerulopathy and related disorders in children","volume":"16","author":"Wong","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib55","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/cells12050712","article-title":"Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 Glomerulopathy","volume":"12","author":"Kovala","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2215\/CJN.0000000000000505","article-title":"Developing therapies for C3 Glomerulopathy","volume":"19","author":"Nester","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2025.12.001_bib57","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib58","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2025.12.001_bib59","article-title":"Clinical predictors of long-term outcomes in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis within the UK RaDaR registry","author":"Masoud","year":"2024","journal-title":"medRxiv"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib61","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.akdh.2025.12.001_bib64","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ndt\/gfab075","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib65","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/ndt\/gfae102","article-title":"Microscopic hematuria in C3G and IC-MPGN","volume":"39","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.34067\/KID.0000000000000115","article-title":"Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy","volume":"4","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Kidney360"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.001_bib67","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/ckj\/sfac108","article-title":"Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy","volume":"15","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.13166","article-title":"The Factor H protein family: the switchers of the complement alternative pathway","volume":"313","author":"Lucientes-Continente","year":"2022","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.001_bib69","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2021101318","article-title":"Factor H\u2013Related protein 1 drives disease susceptibility and prognosis in C3 glomerulopathy","volume":"33","author":"M\u00e1rquez-Tirado","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"9743","key":"10.1053\/j.akdh.2025.12.001_bib70","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","article-title":"Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis","volume":"376","author":"Gale","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.001_bib71","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1681\/ASN.2014040406","article-title":"C4d as a diagnostic tool in proliferative GN","volume":"26","author":"Sethi","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ki.2012.384","article-title":"Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement","volume":"83","author":"Sethi","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1053\/j.akdh.2025.12.001_bib74","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.001_bib75","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.kint.2018.04.004","article-title":"Aliskiren inhibits renin-mediated complement activation","volume":"94","author":"B\u00e9k\u00e1ssy","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib76","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.kint.2023.11.005","article-title":"Renin and renin blockade have no role in complement activity","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib78","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib79","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.001_bib80","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ckj\/sfy127","article-title":"Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy","volume":"12","author":"Bharati","year":"2019","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.001_bib81","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib82","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib83","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib84","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.akdh.2025.12.001_bib85","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2025.12.001_bib86","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1159\/000527166","article-title":"Baseline clinical characteristics and complement biomarkers of patients with C3 Glomerulopathy enrolled in two phase 2 studies investigating the factor D inhibitor danicopan","volume":"53","author":"Podos","year":"2022","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.001_bib87","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy","volume":"36","author":"Bomback","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.001_bib88","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.001_bib89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2024.10.023","article-title":"Iptacopan reduces proteinuria and stabilizes kidney function in C3 Glomerulopathy","volume":"10","author":"Nester","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.akdh.2025.12.001_bib90","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"10512","key":"10.1053\/j.akdh.2025.12.001_bib91","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.001_bib92","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.001_bib93","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of Pegcetacoplan in a phase 2 study of patients with C3 Glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.001_bib94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of Pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"22","key":"10.1053\/j.akdh.2025.12.001_bib95","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.akdh.2025.12.001_bib96","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMe2515157","article-title":"Pegcetacoplan for treatment of C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Zand","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813925001399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813925001399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:08:07Z","timestamp":1793952487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813925001399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2949813925001399"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2025.12.001","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}